Literature DB >> 1594639

Fluctuations in responses to diazepam during the oestrous cycle in the mouse.

M P Carey1, A E Billing, J P Fry.   

Abstract

Administration of diazepam (0.28 mg/kg, IP; 60 min) to male mice or to female mice at oestrus or dioestrus increased the number of transitions made between the light and dark chambers of a test apparatus, a presumed anxiolytic action. However, the same dose of diazepam had no effect on light/dark transitions at late dioestrus, proestrus, or metoestrus II. At metoestrus I, this test dose of diazepam induced a decrease in the number of light/dark transitions and significant changes in other test parameters indicative of an increase in fearfulness or light aversion. Concentrations of diazepam in the brain after intraperitoneal injection were not influenced by the stage of the oestrous cycle, suggesting that the observed changes in responses to diazepam reflect changes in sensitivity to this drug rather than alterations in distribution or metabolism. The results indicate a physiological influence of ovarian steroid hormones on sensitivity to the benzodiazepine tranquilisers.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1594639     DOI: 10.1016/0091-3057(92)90218-5

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  4 in total

1.  The effects of stages of the estrous cycle on pain thresholds in female white rats.

Authors:  E P Vinogradova; D A Zhukov; A S Batuev
Journal:  Neurosci Behav Physiol       Date:  2003-03

2.  Short-term exposure to a neuroactive steroid increases alpha4 GABA(A) receptor subunit levels in association with increased anxiety in the female rat.

Authors:  M Gulinello; Q H Gong; X Li; S S Smith
Journal:  Brain Res       Date:  2001-08-10       Impact factor: 3.252

Review 3.  Effect of Estrous Cycle on Behavior of Females in Rodent Tests of Anxiety.

Authors:  Thelma A Lovick; Hélio Zangrossi
Journal:  Front Psychiatry       Date:  2021-08-31       Impact factor: 4.157

4.  Optimizing prophylactic treatment of migraine: Subtypes and patient matching.

Authors:  Michel Dib
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.